ESC 365 - Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

ESC Premium Access

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Session: Drug therapy in heart failure

Topic: Pharmacologic therapy

Speaker: Professor G. Savarese (Stockholm, SE)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)

64 presentations

16 followers

4 more presentations in this session

State of the art in drug therapy in chronic heart failure.

Speaker: Professor D. van Veldhuisen (Groningen, NL)

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Speaker: Professor W. Kosmala (Wroclaw, PL)

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Speaker: Doctor P. Paren (Gothenburg, SE)

Future direction for research in drug therapy.

Speaker: Professor J. Teerlink (San Francisco, US)

Access the full session

Drug therapy in heart failure

Speakers: Professor G. Savarese, Professor D. van Veldhuisen, Professor W. Kosmala, Doctor P. Paren, Professor J. Teerlink

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources